Product/Composition:- | Praziquantel tablets |
---|---|
Strength:- | 600 mg |
Form:- | Tablets |
Reference Brands:- | Biltricide(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Praziquantel is an antiparasitic that increases membrane permeability to calcium in schistosomes and tapeworms, causing paralysis and death. It effectively treats schistosomiasis, cestodes, and trematodes. Benefits include rapid parasite eradication, symptom relief, reduced transmission, and supporting gastrointestinal and systemic health in parasitic infections worldwide.
Praziquantel tablets, marketed as Biltricide, are approved in the US by the FDA and in the EU via EMA for treating schistosomiasis, tapeworms, and trematodes. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe use, and global availability, helping manage parasitic infections effectively across healthcare regions worldwide.